review_heavy
Review literature is very dense relative to primary central evidence.
supportedtopmoderate inflation risk
Clostridioides difficile
inflammatory bowel disease
Clostridioides difficile looks like a credible signal in inflammatory bowel disease, though some caution is still warranted.
Clostridioides difficile shows a moderate evidence base in inflammatory bowel disease, with multiple central papers and additional supporting literature.
clostridioides_difficile
Credibility score
67
Human translation
5/5
Reproducibility
5/5
Novelty
1/5
Actionability
3/5
Credibility 67Human translation 5/5Reproducibility 5/5Novelty 1/5Actionability 3/5
Why this scores the way it does
- moderate central evidence base
- dense review literature
Main caveats
- directionality and confounding still require curated review
Internal review flags
1 flagsPrimary central evidence
13 papersThe gut microbiome.
2017Australian family physician
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Clostridioides difficile Infection in Children With Inflammatory Bowel Disease.
2020Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Chronic Diarrhea in Adults: Evaluation and Differential Diagnosis.
2020American family physician
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations and Prediction of Functional Profiles of Gut Microbiota After Fecal Microbiota Transplantation for Iranian Recurrent Clostridioides difficile Infection with Underlying Inflammatory Bowel Disease: A Pilot Study.
2022Journal of inflammation research
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Outcomes in patients with inflammatory bowel disease and acute gastrointestinal symptoms who test indeterminate for Clostridioides difficile.
2022Annals of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Molecular characterization and antibiotic resistance of Clostridioides difficile in patients with inflammatory bowel disease from two hospitals in China.
2022Journal of global antimicrobial resistance
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection.
2023Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Diarrheal-associated gut dysbiosis in cancer and inflammatory bowel disease patients is exacerbated by Clostridioides difficile infection.
2023Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases.
2024Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection.
2024The American journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Comparative Efficacy of Fecal Microbiota Transplantation in Treating Refractory or Recurrent Clostridioides difficile Infection among Patients with and without Inflammatory Bowel Disease: A Retrospective Cohort Study.
2024Biomedicines
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection.
2025Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study.
2025Journal of Crohn's & colitis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Supporting primary evidence
1 papersGut Microbiota Associated with Clostridioides difficile Carriage in Three Clinical Groups (Inflammatory Bowel Disease, C. difficile Infection and Healthcare Workers) in Hospital Field.
2023Microorganisms
Human primary paper with plausible association relevance to the disease context.
Preclinical supporting evidence
4 papersIntestinal Inflammation and Altered Gut Microbiota Associated with Inflammatory Bowel Disease Render Mice Susceptible to Clostridioides difficile Colonization and Infection.
2021mBio
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Host Sorbitol and Bacterial Sorbitol Utilization Promote Clostridioides difficile Infection in Inflammatory Bowel Disease.
2023Gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Antibiotic use and risk of Clostridioides difficile infection in patients with inflammatory bowel disease.
2024Journal of gastroenterology and hepatology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bacteriocin-transport-inspired oral peptide-probiotic delivery ameliorates IBD complications via autophagy and gut homeostasis.
2026Science advances
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
38 papersClostridium difficile and inflammatory bowel disease.
2008Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Clostridium difficile and inflammatory bowel disease.
2009Gastroenterology clinics of North America
Relevant review or meta-analysis for the signal-disease area.
Clostridium difficile infection and inflammatory bowel disease.
2014The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Pseudomembranous colitis.
2015Disease-a-month : DM
Relevant review or meta-analysis for the signal-disease area.
Clostridium difficile infection in inflammatory bowel disease: challenges in diagnosis and treatment.
2017Clinical journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities.
2017World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Digestive disorders and Intestinal microbiota.
2018Acta bio-medica : Atenei Parmensis
Relevant review or meta-analysis for the signal-disease area.
The Juncture Between Clostridioides difficile Infection and Inflammatory Bowel Diseases.
2019Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Relevant review or meta-analysis for the signal-disease area.
Thirty Years of Lactobacillus rhamnosus GG: A Review.
2019Journal of clinical gastroenterology
Relevant review or meta-analysis for the signal-disease area.
MICROBIOTA INSIGHTS IN CLOSTRIDIUM DIFFICILE INFECTION AND INFLAMMATORY BOWEL DISEASE.
2020Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Management of Clostridioides difficile infection in patients with inflammatory bowel disease.
2021Intestinal research
Relevant review or meta-analysis for the signal-disease area.
Bacteriotherapy for inflammatory bowel disease.
2021Inflammation and regeneration
Relevant review or meta-analysis for the signal-disease area.
Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease.
2021Current opinion in gastroenterology
Relevant review or meta-analysis for the signal-disease area.
The Elevated Risk of Recurrent Clostridioides Difficile Infection in Patients with Inflammatory Bowel Disease: a Systematic Review and Meta-analysis.
2021Clinical laboratory
Relevant review or meta-analysis for the signal-disease area.
The interplay of Clostridioides difficile infection and inflammatory bowel disease.
2021Therapeutic advances in gastroenterology
Relevant review or meta-analysis for the signal-disease area.
The gut microbiota and gut disease.
2021Internal medicine journal
Relevant review or meta-analysis for the signal-disease area.
Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives.
2022Computational and structural biotechnology journal
Relevant review or meta-analysis for the signal-disease area.
Histological features of Clostridioides difficile colitis in patients with inflammatory bowel disease.
2022Histopathology
Relevant review or meta-analysis for the signal-disease area.
Risk Factors, Diagnosis, and Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease.
2022Microorganisms
Relevant review or meta-analysis for the signal-disease area.
The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management.
2022Gut microbes
Relevant review or meta-analysis for the signal-disease area.
[Clostridioides Infection in Patients with Inflammatory Bowel Disease].
2022The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Relevant review or meta-analysis for the signal-disease area.
Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: A systematic review and meta-analysis.
2023Journal of autoimmunity
Relevant review or meta-analysis for the signal-disease area.
Clostridium difficile in inflammatory bowel disease.
2023Current opinion in gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease.
2023Current gastroenterology reports
Relevant review or meta-analysis for the signal-disease area.
Clostridioides difficile Infection in Inflammatory Bowel Disease Patients: A Systematic Review of Risk Factors and Approach in Management.
2023Cureus
Relevant review or meta-analysis for the signal-disease area.
Review Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future.
2023Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Relevant review or meta-analysis for the signal-disease area.
Clostridioides difficile infection in inflammatory bowel disease: a clinical review.
2024Expert review of anti-infective therapy
Relevant review or meta-analysis for the signal-disease area.
Colorectal Disease and the Gut Microbiome: What a Surgeon Needs to Know.
2024The Surgical clinics of North America
Relevant review or meta-analysis for the signal-disease area.
Fecal microbiota transplantation: current challenges and future landscapes.
2024Clinical microbiology reviews
Relevant review or meta-analysis for the signal-disease area.
Current and future microbiome-based therapies in inflammatory bowel disease.
2024Current opinion in gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Diagnosis and Management of Clostridioides difficile in Inflammatory Bowel Disease.
2025The American journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Clostridioides difficile infection: an update.
2024Le infezioni in medicina
Relevant review or meta-analysis for the signal-disease area.
Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis.
2024BMC gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.
2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Relevant review or meta-analysis for the signal-disease area.
Precision microbiota therapy for IBD: premise and promise.
2025Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Global Patterns of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Prevalence, Epidemiology, and Risk Factors.
2025Crohn's & colitis 360
Relevant review or meta-analysis for the signal-disease area.
Intestinal Microbiota and Fecal Transplantation in Patients with Inflammatory Bowel Disease and Clostridioides difficile: An Updated Literature Review.
2025Journal of clinical medicine
Relevant review or meta-analysis for the signal-disease area.
Akkermansia muciniphila: A key player in gut microbiota-based disease modulation.
2025Microbiological research
Relevant review or meta-analysis for the signal-disease area.